NIRI Appoints Charles Triano to Board of Directors
The National Investor Relations Institute (NIRI) today announced the appointment of Charles (Chuck) Triano to the NIRI Board of Directors. Triano is Senior Vice President, Investor Relations, for Pfizer (NYSE: PFE), a leading global biopharmaceutical company. He replaces William (Bill) Walkowiak who retired and stepped down from the NIRI Board earlier this year. Triano's appointment is through December 2013 when NIRI members will vote to approve him to serve the remainder of Walkowiak's term ending in December 2014 at the NIRI annual meeting.
“I am very pleased to welcome Chuck Triano to the NIRI Board and look forward to his contributions. NIRI is fortunate to have such high caliber, committed volunteer members such as Chuck,” said Jeffrey D. Morgan, President and Chief Executive Officer of NIRI. “I also want to recognize Bill Walkowiak for his service to NIRI. A longtime NIRI member, Bill's selfless volunteer work at both the local chapter and national levels has made NIRI a better organization. I will miss Bill and wish him the very best in his well-deserved retirement.”
Hulus Alpay, NIRI Board Chairman and Head of Investor Relations for Medidata Solutions Inc. (NASDAQ: MDSO), a leading global provider of cloud-based clinical technology solutions, said, “I am delighted to welcome Chuck to the NIRI Board of Directors. I appreciate his willingness to serve, and I am confident that he will continue to make significant contributions to NIRI. On behalf of the Board, I also want to thank Bill for his tireless commitment to NIRI and the IR profession over the years, and wish him the very best in the next great chapter of his life.”
Mr. Triano joined Pfizer in 2008, and is responsible for all global Investor Relations functions. In addition to Investor Relations, Pfizer's Operations Planning and Analysis department reports to Mr. Triano. He is also a member of Pfizer's Finance and Business Operations Leadership Team and reports directly to the Chief Financial Officer. Subsequent to his appointment, Pfizer's Investor Relations Program has been ranked annually among the top programs within the healthcare sector by Institutional Investor Magazine, based on a survey of institutional portfolio managers and analysts.
Prior to Pfizer, Triano served as the Vice President of Investor Relations at Forest Laboratories (NYSE: FRX) beginning in 2000. He initiated the company's first formal investor relations and corporate communications program. During his tenure, Forest's Investor Relations program was twice ranked among the top three programs in the entire healthcare sector by Institutional Investor Magazine. Triano served as Director of Investor Relations at Bristol-Myers Squibb Company (NYSE: BMY) prior to joining Forest Laboratories. He was also a Managing Director at The Carson Group (acquired by Thomson Financial in 2000), a financial information organization specializing in global shareholder research and capital markets intelligence.
Triano has been a speaker at numerous NIRI seminars and conferences, as well as serving as a member of the NIRI Annual Conference Committee. He has also been a guest lecturer at the Fordham University Masters of Investor Relations program. He holds a B.A. from the University of Connecticut and has completed several certificate programs in the areas of finance and investor relations.
About the National Investor Relations Institute (NIRI)
Founded in 1969, NIRI (www.NIRI.org) is the professional association of corporate officers and investor relations consultants responsible for communication among corporate management, shareholders, securities analysts and other financial community constituents. NIRI is the largest professional investor relations association in the world with more than 3,300 members representing over 1,600 publicly held companies and $9 trillion in stock market capitalization.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.